USCAP Companion Meetings

When: Back to Calendar 2 Mar / 2014 @ 7:30 pm - 8:30 pm
Where: San Diego Convention Center
111 West Harbor Drive
San Diego,CA 92101
USA

If you are attending the USCAP Annual Meeting, please participate in the

AMERICAN SOCIETY OF CYTOPATHOLOGY COMPANION MEETINGS

Sunday March 2, 2014
San Diego Convention Center
San Diego, California

Sunday, March 2, 2014 at 7:30 PM convention-center

The Quest for Standardization of Urine Cytology Reporting
 - The Evolution of the Paris System

 

Moderator
Dr. Eva M. Wojcik, Loyola University Medical Center, Maywood, Illinois

From Bethesda to Paris – Establishing Standardized Reporting Systems
Dr. Ritu Nayar, Northwestern University, Feinberg school of Medicine, Chicago, Illinois

Urine Cytology – What Really Matters? Pathogenesis of Urothelial Carcinoma
Dr. Eva M. Wojcik, Loyola University Medical Center, Maywood, Illinois

Urine Cytology Reports – What is significant for me? The Urologist’s Perspective
Dr. Marcus Quek, Loyola University Medical Center, Maywood, Illinois

Adequacy Criteria for Instrumented Urines (Finally!) and Proposed Diagnostic Categories and Frequencies
Dr. Güliz Barkan, Loyola University Medical Center, Maywood, Illinois

What do we need to call Urine “Positive”?
Dr. Dorothy Rosenthal, Johns Hopkins School of Medicine, Baltimore, Maryland

What Adjunct Tests Should We Use and When?
Spasanija Savic Prince, MD, University Hospital Basel, Basel, Switzerland

 

The ASC is the largest organization of cytopathologists and cytotechnologists in the United States with education as one of its primary missions. The need for standardization of urine cytology has been voiced through the ASC membership listserve on numerous occasions. The initial idea for pursuing developing terminology for urinary cytology came from ASC members, led by Drs. Rosenthal and Wojcik. This topic was further developed by members of the ASC and International Academy of cytology (IAC) at a recent conference in Paris. The ASC Executive Board approved the presentation of this topic at the 2014 USCAP meeting and the officers of the ASC and IAC were involved in the process of planning and selection of speakers.

Practicing pathologists, fellows and residents in training

In spite of the early acceptance in the mid-twentieth century of George Papanicolaou’s hypothesis that microscopic evaluation of exfoliated epithelial cells was a potential cancer screening method, exfoliative cytology for urinary tract malignancies has had poor accuracy and reproducibility. However, urine cytology comprises a significant percentage of daily non-GYN volume in any cytopathology practice, and continues to be one of the most difficult and frustrating specimens pathologists encounter daily. Problems include inadequate cellularity of samples, cellular degeneration prior to fixation, subtle changes within cells from low grade lesions, as well as unrealistic expectations for diagnosing low grade lesions on cytology. Most importantly, however, there is lack of a standardized/ comprehensive reporting system for urinary cytology that is based on the understanding of pathogenesis of the urothelial carcinoma and the clinical significance of various types of urinary tract neoplastic lesions. Although over ten years ago there was an attempt to create such a system, it has never been fully implemented in daily practice. In recognition of this need, a panel of experts convened at the 18th International Congress of Cytology meeting in Paris (May 2013) to discuss ways to improve the reporting and performance of urinary cytology, and to evaluate novel tests to assist in the non-invasive screening and diagnosis of urinary neoplasms. This session will be a follow up on the work of this “Paris Group”.

Upon completion of this activity, participants should be better able to:
• Understand the pathogenesis of urothelial carcinoma and its histologic and cytologic presentations
• Appreciate the clinical significance of various diagnostic categories in urinary cytology and use standardized terminology for urinary cytology based upon clinical outcomes
• Use evidence-based criteria to assess adequacy of instrumented urines
• Recognize characteristic morphologic features in urinary specimens necessary to make a clinically significant diagnosis
• Implement and evaluate results of ancillary studies in urinary tract specimens